Find recruiting clinical trials for Chronic Obstructive Pulmonary Disease in the UK — from bronchodilator optimisation to biologic therapies. See where trials fit into your treatment pathway.
Free to use · Live data from ClinicalTrials.gov · Updated daily
See where clinical trials fit into your treatment journey
First-line relief when symptoms are intermittent
Standard: SABA (salbutamol) or SAMA (ipratropium) as needed
Regular maintenance therapy for persistent symptoms
Standard: Long-acting beta-agonists + long-acting muscarinic antagonists (dual bronchodilation)
When frequent exacerbations occur despite dual therapy
Standard: LABA + LAMA + ICS (e.g. Trelegy, Trimbow) — single inhaler triple therapy
For patients with eosinophilic COPD or uncontrolled exacerbations
Standard: Benralizumab, dupilumab, or novel anti-inflammatory biologics
Chronic Obstructive Pulmonary Disease is a progressive lung condition causing breathing difficulty, chronic cough, and frequent chest infections. Affects about 1.2 million people in the UK. Main cause is smoking, but occupational exposure and genetics also play a role.
Despite current treatments, many COPD patients still have frequent exacerbations (flare-ups) that hospitalise them. Trials are testing new anti-inflammatory biologics, inhaled therapies, and pulmonary rehabilitation approaches.
About 20-30% of COPD patients have elevated eosinophils — a type of white blood cell. These patients may respond particularly well to biologic therapies, similar to severe asthma treatment. Trials specifically target this subgroup.
Loading trials from ClinicalTrials.gov...